The New Jersey-based company's shares fell 1.6% in extended trading. The drug, mavacamten, was tested in adult patients with ...

Bristol Myers Squibb (BMY) closed the most recent trading day at $49.33, moving -1.35% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 2.24%. Elsewhere, ...

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive ...

This was the stock's second consecutive day of losses.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol-Myers Squibb (BMY – Research Report) and ...

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new ...

Bristol Myers Squibb won the dismissal of a proposed class action accusing it of fraudulently obtaining patents and filing ...

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report). The company’s ...

I will continue by comparing the revenue growth rates of Merck and Bristol-Myers Squibb, how often these two giants beat Wall Street analysts' expectations, and also compare their price-to-sales ...

Bristol Myers Squibb pays investors a very attractive dividend that yields 4.1%. The company reported a loss last year, but that was a result of non-recurring expenses. Free cash flow looked ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The stock's fall snapped a two-day winning streak.